SCRI Development Innovations
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SCRI Development Innovations sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
SCRI Development Innovations: 146 sponsored US clinical trials, 5 recruiting.
SCRI Development Innovations sponsors 146 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 125 completed. 2 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
SCRI Development Innovations ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
125 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 1 of 3
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT07011576
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT05748834
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
NCT04402138
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT04200365
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
NCT04209725
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
NCT03977467
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
NCT03436862
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
NCT02859064
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
NCT02887248
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
NCT02795156
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT02843074
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
NCT02649673
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
NCT02386826
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
NCT02318784
Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC
NCT02436772
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
NCT02317991
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT02254551
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
NCT02291913
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02125084
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
NCT02168101
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
NCT02195011
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
NCT02113007
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
NCT01934894
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
NCT01990209
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
NCT01487265
Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
NCT01844817
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
NCT01848145
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
NCT01829113
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
NCT01871675
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
NCT01769508
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
NCT01749956
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
NCT01626352
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
NCT01522833
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
NCT01611857
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
NCT01527487
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
NCT01490866
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
NCT01349660
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
NCT01404650
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT01496118
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT01401959
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
NCT01343498
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
NCT01048099
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
NCT01226719
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
NCT01226732
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01113632
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
NCT01154335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 105 |
| Phase 3 | 2 |
What is open in the SCRI Development Innovations pipeline
5 recruiting of 146 indexed (3% open); 125 completed (86%).
Phase mix: 2 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SCRI Development Innovations: open-pipeline peers nationwide
Peers matched on 146 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
SCRI Development Innovations sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Medtronic MiniMed · 3% recruiting · 29 trials
- Sandoz · 3% recruiting · 29 trials
- Sonova · 3% recruiting · 29 trials
- USDA Beltsville Human Nutrition Research Center · 3% recruiting · 29 trials
Related
What to do with this SCRI Development Innovations page
146 registered trials is a research-attention snapshot, not an endorsement of SCRI Development Innovations or any single study.
- 5 of SCRI Development Innovations's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition SCRI Development Innovations studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SCRI Development Innovations pipeline card: 146 registered trials from official public datasets.Report a data error.